Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Megestrol Acetate +/- Metformin for Endometrial Intraepithelial Neoplasia
NCT04576104Phase 2Active, not recruiting
- Sponsor
- Northwestern University
- Start
- Nov 2021
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of liquid metformin (Aspargo Labs) in Endometrial intraepithelial neoplasia (EIN) (2 arms), sponsored by Northwestern University. Primary endpoint: Percentage of Ki-67 positive cells. Started Nov 2021; status: active, not recruiting.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
Endometrial intraepithelial neoplasia (EIN)
Beyond the preview
Go deeper on NCT04576104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04576104.